As of 1 April 2026, the PSJD database will become an archive and will no longer accept new data.
Current publications from Polish scientific journals are available through the Library of Science: https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 2

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  SCLC
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

Intraocular metastasis of small cell lung cancer: a case report

100%
Pażyra A., Kusak N., Żak N., Jaworska B.
OncoReview
|
2023
|
vol. 13
|
issue 4
99-102
EN
We report a rare case of intraocular metastasis of small cell lung cancer with disease progression.
2
Publication available in full text mode
Content available

The current state of knowledge on small cell and non-small cell lung cancer and the position of durvalumab immunotherapy in lung cancer treatment

75%
Poboży K., Domańska J., Domański P.
OncoReview
|
2022
|
vol. 12
|
issue 4
75-82
EN
Lung cancer is the second most frequently diagnosed cancer and the leading cause of cancer-related deaths in the world. These statistics make lung cancer one of the most important targets for modern medicine. The identification of multiple risk factors, including tobacco smoking, has been fundamental in understanding the disease. Late-stage detection is a significant contributor to the high mortality rate of lung cancer. Nonetheless, the role of screening is still debatable. The selection of therapy is primarily based on distinguishing between small-cell and non-small cell lung cancer. Despite the major differences in treatment, in both types in specific situations the treatment involves durvalumab – a monoclonal antibody targeting the programmed cell death ligand 1 molecule, which is often present on tumor cells and protects them against the patient’s immune system. The efficacy of durvalumab has been demonstrated in two randomized, multicenter clinical trials. The aim of this study is to summarize the current state of knowledge about lung cancer and durvalumab. Despite the current 5-year survival rate of 19% in lung cancer, the development of immunotherapeutics such as durvalumab may be the key to improving the unfavorable prognosis of lung cancer in the future.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.